Common Drugs for Managing Canine Atopic Dermatitis
This course will be accessible on 21 June 2024 (CEST).
The focus of this lecture will be on the most common non-steroidal symptomatic allergy therapies we have available to us today- cyclosporine, oclacitinib and lokivetmab.
The focus of this lecture will be on the most common non-steroidal symptomatic allergy therapies we have available to us today- cyclosporine, oclacitinib and lokivetmab.
-
Access
Live Webinar -
Study Time / CPD
1 hour -
Language
English -
Access Duration
12 months